A report in September 2009 from Health and Human Services' Agency for Healthcare Research and Quality suggests that<unk> , raloxifene, and tibolone used to treat breast cancer significantly reduce invasive breast cancer in midlife and older women, but also increase the risk of adverse side effects. Endometrial cancer<unk>  is a selective estrogen receptor modulator (SERM). Even though it is an antagonist in breast tissue it acts as partial agonist on the endometrium and has been linked to endometrial cancer in some women. Therefore, endometrial changes, including cancer, are among<unk> 's side effects. With time, risk of endometrial cancer may be doubled to quadrupled, which is a reason<unk>  is typically only used for five years. The American Cancer Society lists<unk>  as a known carcinogen, stating that it increases the risk of some types of uterine cancer while lowering the risk of breast cancer recurrence. Cardiovascular and metabolic<unk>  treatment of postmenopausal women is associated with beneficial effects on serum lipid profiles. However, long-term data from clinical trials have failed to demonstrate a cardioprotective effect. For some women,<unk>  can cause a rapid increase in triglyceride concentration in the blood. In addition, there is an increased risk of thromboembolism especially during and immediately after major surgery or periods of immobility. Use of<unk>  has been shown to slightly increase risk of deep vein thrombosis, pulmonary embolism, and stroke. Liver toxicity<unk>  has been associated with a number of cases of hepatotoxicity. Several different varieties of hepatotoxicity have been reported.<unk>  can also precipitate non-alcoholic fatty liver disease in obese and overweight women (not in normal weight women) at an average rate of 40% after a year use with 20 mg/day.
Tamoxifen
Endoxifen
N-Desmethyltamoxifen
Anastrozole
Salvestrol
Bazedoxifene
N,N-Didesmethyltamoxifen
Exemestane